Start with the part of this story Silicon Valley's own myth leaves out: Boston got there first. Route 128, the circumferential highway through Boston's suburbs, was completed by 1956 and became the nation's first real high-tech corridor -- years before "Silicon Valley" was a phrase anyone used.^[1] The mechanism was the identical one this site already traced in California: federal defense money, funneled through a research university, spilling out into commercial companies built by the same engineers who did the classified work.

The anchor was MIT Lincoln Laboratory, and its founding contract alone tells the scale. On July 26, 1951, the Air Force, Army, and Navy jointly chartered Project Lincoln -- an MIT-run research center built to develop SAGE, the country's first continent-wide, computerized air defense system.^[2] Its roots traced back to the MIT Radiation Laboratory, spun up out of the physics department during World War II to build radar for the Allied war effort.^[2] By the time SAGE reached full deployment in 1963, its total cost had exceeded the Manhattan Project's.^[2] In 1957, Ken Olsen -- an MIT engineer who had worked at Lincoln Lab building the Memory Test Computer and the early transistor-based TX-0 and TX-2 machines -- took that federally funded expertise directly into Digital Equipment Corporation, founded in Maynard.^[1] By the 1960s, Data General, GTE, and Analogic had followed DEC onto the same corridor.^[1]

By every obvious measure, Route 128 should have won. It had the earlier defense contracts, the university, and a five-year head start on Silicon Valley's own emergence. A landmark 1994 study, Regional Advantage by AnnaLee Saxenian, found the real reason it lost anyway, and it wasn't resources.^[3] Route 128's corporations were vertically integrated and secretive, run by older, Harvard-educated executives who modeled themselves on General Motors and General Electric -- skill and technology stayed locked inside each individual firm.^[3] Silicon Valley ran the opposite structure: open, horizontal communication between competing firms and a fluid labor market that let ideas and engineers move fast between companies.^[3] The gap this produced was not marginal -- Silicon Valley generated triple the new jobs of Route 128 between 1975 and 1990, and its firms' combined market value grew $25 billion from 1986 to 1990 alone, against just $1 billion of growth for Route 128's firms over the identical window.^[3] A twenty-five-to-one gap in value creation, between two regions that started from the same defense-funded, MIT/Stanford-anchored playbook.

"Modeled themselves on General Motors" was not a loose comparison -- the two were institutionally connected at the root. Alfred P. Sloan Jr., GM's own president and CEO from 1923 to 1946, was an MIT alumnus who gave his alma mater more than $5 million in 1950 to establish what became MIT's School of Industrial Management, opened in 1952 and renamed the MIT Sloan School of Management in his honor in 1964.^[4] Route 128's executives weren't just imitating GM's hierarchy from a distance. Many of them were trained inside a business school GM's own chairman built and funded -- the same management culture Saxenian found too closed to compete, quite literally endowed by the company it was copying.

What Route 128 lost in computing, Cambridge kept in a completely separate industry, for a reason that had nothing to do with corporate culture at all. In 1978, MIT's Phillip Sharp and Harvard's Walter Gilbert -- who would win the Nobel Prize in 1993 for his split-gene research -- co-founded Biogen with British biologist Kenneth Murray, the first company to hold a commercial license for recombinant DNA technology.^[5] Biogen opened first in Switzerland, then relocated specifically to Cambridge -- Gilbert's own reason, on record: "Cambridge already has a discipline about how to handle recombinant DNA," a real regulatory readiness other cities hadn't built yet.^[5] When Biogen won its first FDA approval in 1989, for a recombinant hepatitis B vaccine, other biotech companies -- Genzyme among them -- took notice and began migrating to Kendall Square themselves.^[5] Cambridge became what MIT's own news office now calls the birthplace of biotech, built on a regulatory-readiness advantage the same way San Diego's biotech cluster was built on a deliberate 1965 zoning choice -- two different mechanisms, same result: an industry choosing a place because the place was specifically ready for it.

And the same divergence Saxenian measured in 1994 is still exactly the shape of this site's own graph in 2026. Boston today holds 103 companies tagged Biotech/Pharma against just 6 tagged Semiconductors/Hardware -- a roughly seventeen-to-one ratio, in the same direction and nearly the same order of magnitude as the twenty-five-to-one value gap Saxenian found three decades ago. The industry Route 128 lost never came back. The industry Cambridge built instead never left.